Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. - Wikidata - wikimedia - TriplyDB

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

http://www.wikidata.org/entity/Q35361496

about

Molecular reclassification of Crohn's disease by cluster analysis of genetic variants Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification New serological markers in inflammatory bowel disease are associated with complicated disease behaviour Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype TNFSF15 is an ethnic-specific IBD gene Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations Novel biomarkers of fibrosis in Crohn's disease The multidisciplinary health care team in the management of stenosis in Crohn's disease Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a mul Immune therapy in inflammatory bowel disease and models of colitis.Factors associated with disease evolution in Greek patients with inflammatory bowel disease.Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.New proteomic approaches for biomarker discovery in inflammatory bowel disease.Management of active Crohn disease.Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts.Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction New strategies for treatment of inflammatory bowel disease Current and future role of biomarkers in Crohn's disease risk assessment and treatment.High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype.Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease Predictors of aggressive inflammatory bowel disease.Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans Clinical, serological and genetic predictors of inflammatory bowel disease course.Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management.Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease Risk factors for repeat abdominal surgery in korean patients with Crohn's disease: a multi-center study of a korean inflammatory bowel disease study group.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression Immunogenetic phenotypes in inflammatory bowel disease.Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases.Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

P2860

Q21562166-53CF3E43-EFBF-4D4D-8C45-E094CA62D80A Q22241487-4775FCF2-2C2A-4045-8C3C-B597FF561C3F Q22242048-16257DBA-0ED6-4381-8BE5-A2CDFF1710E0 Q22242053-B7B386F0-7429-4ACF-BB38-EA2F0DEE9A24 Q22251117-8541F805-6B8B-4C57-BA05-4EB28C5E4E87 Q24644834-AF4D88FE-FABB-4806-804B-9F5053A648C2 Q24684357-70B53FD8-6E62-4B23-A6D3-EAE25E7C4274 Q26738287-448F943D-C779-400B-A6BE-FD6952BADCCD Q28088702-BDFB2310-6730-45D6-AA5E-EED5E8C1DBCD Q28303013-82DFBFFC-1A6D-4DF5-A955-DD5B765625F9 Q30774968-42AA3656-E273-43F6-A029-45D600ADA7E2 Q30820594-98372A4F-AF40-4802-B50B-3A6B41F1451D Q33894195-DA082DA2-0589-49BD-8937-8D49497D7F94 Q34013076-05E0C3ED-D6C9-4F22-BF45-6A1F0A55EE6B Q34072574-9F0327F4-67AF-4168-A310-0325A4504EB4 Q34096526-57DF01DB-ADA5-4EF6-801C-D6D1F5B1E110 Q34345967-05F59319-54E5-438B-913A-CE12DBC46C3B Q34373603-FB06F9F0-BC13-4371-A149-2E3EE1EAAD1A Q35045292-1A8C96DA-88A1-4126-83E0-5A4276614E09 Q35058495-21D2CB72-22EA-4EBC-AE29-40D13182CE50 Q35061825-4856EDE9-928B-4AEB-B616-68FF2BEED84F Q35069777-2448B035-7BA6-4669-9C8E-40BF19A3EBD2 Q35095265-2A10A181-EB8C-4BEB-95D5-ECAD08CBDE28 Q35365755-E89E60CC-2251-4DC1-8044-96307BB7C914 Q35552641-01BEFBC7-7E01-4E7A-90DC-0C24C361368A Q35595508-F4B1335C-69D7-4549-A0A1-D33F1DF9FFE2 Q35596732-50323517-59A7-42CC-A7DB-71EEDE3C4C2B Q35597688-35A1AD8D-2CE7-4013-93D6-94AD8F74B61D Q35691407-90CA812A-014C-4947-BF9C-81F384FD70F8 Q35748693-58E1757A-D676-4B26-84D6-D658B69EEDE5 Q35919095-42970E68-6AA4-4F2B-8035-413BE51C4109 Q36144470-52E03604-7600-44F2-9EBB-476D5024514A Q36171739-C68CCA61-F725-4C60-8F5D-1BF2DC656A9D Q36172755-C266A385-E863-4AD7-BAD7-B00A9C01722B Q36229973-5D74BF5F-41A2-4EB2-B42C-2FC4EB077E3B Q36477912-57D313AB-B6F2-4263-B7A8-CCD8356E3E18 Q36484765-1794E73B-E986-4333-87B3-FA54D8154754 Q36506455-70CCD557-C320-43AD-8831-03CE49C000EE Q36702482-D4A32F61-65CA-4388-8C69-59CBA7E81E03 Q37064590-FDDE67F3-4EE2-4D3B-82FC-53FBEF247900

P2860

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

http://www.wikidata.org/entity/Q35361496

description

2000 nî lūn-bûn

@nan

2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Marker antibody expression str ...... inct clinical characteristics.

@ast

Marker antibody expression str ...... inct clinical characteristics.

@en

type

label

Marker antibody expression str ...... inct clinical characteristics.

@ast

Marker antibody expression str ...... inct clinical characteristics.

@en

prefLabel

Marker antibody expression str ...... inct clinical characteristics.

@ast

Marker antibody expression str ...... inct clinical characteristics.

@en

P1433

Q35361496-47AFF9F6-48E8-44E6-9FC3-21B369F368F2

P1476

Q35361496-0F46A9B9-AAF5-450A-9E46-69C1B1E65B9E

P2093

Q35361496-2B001680-D1EB-4DDF-BDFB-FDB232141792

Q35361496-661D32EC-F3B2-4905-B3A9-1C2C9598D908

Q35361496-69BA1CD0-EFE1-474D-8706-69923069E3F7

Q35361496-C363BC0A-C613-477E-80DC-F6B1CB934591

Q35361496-D4B4CF36-FC42-47B4-9C11-F540B3266EDF

Q35361496-DF847C3D-5D27-4B3E-A461-4CD0307ABA44

P2860

Q35361496-0D95310D-6937-4305-90FF-ABFEC6A8DA2E

Q35361496-0DBE5FFA-53AC-4341-B197-5839465E2358

Q35361496-18338962-7D6A-4CA5-A8B0-A61226222D45

Q35361496-1E56FC52-F966-416E-91F9-26FED3637589

Q35361496-22D20340-BD3A-4585-9350-7B27B7BB5E72

Q35361496-23D4AA55-98BE-46B9-A65B-D465917F5F07

Q35361496-33A91323-955A-4208-82E4-FC8A29FCE937

Q35361496-35191DA1-E1C2-4FF6-B0BA-320DC160F4FD

Q35361496-3C232F74-2534-4866-922F-5D7E7F3DE1E8

Q35361496-3EDB2BEC-6481-4E32-ABDC-AD2BA6E23F3A

P304

Q35361496-6971FA15-3301-4DA3-91EF-C8693C6F5A9F

P31

Q35361496-8670C20C-5F88-47A7-A5E2-B832189BCEA4

P356

Q35361496-B2D92905-1FC3-43EE-8153-EE7D261096FB

P407

Q35361496-EC41C592-FB49-4E85-827E-952CDC3EFD31

P433

Q35361496-C1D72FE0-57D2-4C5B-B4DD-C0F7467D8FCE

P478

Q35361496-A6D32646-0295-4371-8E8A-C0FA5E71D60D

P577

Q35361496-1696460E-EB1C-43C4-9B5A-5F27E4A9D54C

P5875

Q35361496-46D6A371-1628-469E-9B88-C60A649A3159

P698

Q35361496-467092E5-8ACC-4BC4-AC72-68BF2D6EF412

P921

Q35361496-35D09799-CBB3-4812-A058-E676C1C77E15

Q35361496-B8DF507E-B8CD-4B3D-B0E6-7635B3E8CEC8

P932

Q35361496-BF10B427-AE5F-47C4-A01A-C79B64AA0B6D

P356

P1433

P1476

Marker antibody expression str ...... inct clinical characteristics.

@en

P2093

E A Vasiliauskas

http://www.w3.org/2001/XMLSchema#string

H Yang

http://www.w3.org/2001/XMLSchema#string

J Gaiennie

http://www.w3.org/2001/XMLSchema#string

L C Karp

http://www.w3.org/2001/XMLSchema#string

L Y Kam

http://www.w3.org/2001/XMLSchema#string

S R Targan

http://www.w3.org/2001/XMLSchema#string

P2860

Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews

Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease

Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance

Specific antibody response to oligomannosidic epitopes in Crohn's disease

Investigation of the association of major histocompatibility complex genes, including HLA class I, class II and TAP genes, with clinical forms of Crohn's disease

Progression of allergy and asthma through childhood to adolescence.

Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers.

Predictability of the postoperative course of Crohn's disease.

Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.

Clinical patterns of familial inflammatory bowel disease

P304

487-496

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.47.4.487

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277469927

http://www.w3.org/2001/XMLSchema#string

P698

10986208

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

1728065

http://www.w3.org/2001/XMLSchema#string